A pharmaceutical composition for preventing or treating female climacteric syndromes comprising Loganin which increases the concentration of estradiol (17-estradiol, E2) in the blood of a menopausal mouse model and has shown efficacies such as an increase in the estrogen receptor alpha expression in the uterus, which remedies uterine contraction and degeneration, and decreases in the accumulation and the size of adipocytes in liver and the abdominal adipose tissues and the liver and weight loss, a derivative thereof or a pharmaceutically acceptable salt thereof as an active ingredient.

The present disclosure relates to a controlled release complex of a carboxylated polymer having carboxyl groups having a degree of substitution of about 0.1 to about 1.0, forming a complex through ionic interaction with an antimalarial alkaloid extract; a solid oral dosage form comprising the same, and a solid oral dosage form comprising an antimalarial drug combination which comprises the controlled release complex of the present invention and an antimalarial drug.

The present disclosure relates to a controlled release complex of a carboxylated polymer having carboxyl groups having a degree of substitution of about 0.1 to about 1.0, forming a complex through ionic interaction with an antimalarial alkaloid extract; a solid oral dosage form comprising the same, and a solid oral dosage form comprising an antimalarial drug combination which comprises the controlled release complex of the present invention and an antimalarial drug.

The present disclosure provides Diels-Alder adducts of chalcone and prenylphenyl moieties capable of modulating the activity of cannabinoid receptors, and to oligomers of flavan-3-ol capable of modulating fat absorption and storage. Such Diels-Alder adducts of chalcone and prenylphenyl moieties or oligomers of flavan-3-ol can optionally be used in combination with other weight management agents, such as anorectic agents, a lipase inhibitors, other cannabinoid receptor modulators, psychotropic agents, insulin sensitizers, stimulants, or satiety agents, as well as to methods of use thereof such as treating or preventing weight gain or obesity, promoting weight loss, appetite suppression, modifying satiety, or the like.

The present disclosure provides Diels-Alder adducts of chalcone and prenylphenyl moieties capable of modulating the activity of cannabinoid receptors, and to oligomers of flavan-3-ol capable of modulating fat absorption and storage. Such Diels-Alder adducts of chalcone and prenylphenyl moieties or oligomers of flavan-3-ol can optionally be used in combination with other weight management agents, such as anorectic agents, a lipase inhibitors, other cannabinoid receptor modulators, psychotropic agents, insulin sensitizers, stimulants, or satiety agents, as well as to methods of use thereof such as treating or preventing weight gain or obesity, promoting weight loss, appetite suppression, modifying satiety, or the like.

Homeopathic compositions and formulations are disclosed. In one embodiment, compositions and formulations are disclosed that aid in weight loss and maintenance of a healthy weight. In another embodiment, methods are disclosed for producing homeopathic compositions and formulations. In still another embodiment, methods are disclosed for helping an individual lose weight.

Homeopathic compositions and formulations are disclosed. In one embodiment, compositions and formulations are disclosed that aid in weight loss and maintenance of a healthy weight. In another embodiment, methods are disclosed for producing homeopathic compositions and formulations. In still another embodiment, methods are disclosed for helping an individual lose weight.

Therapeutic patches are presented including: a non-permeable sealing layer; a pressure sensitive adhesive layer bonded along the non-permeable sealing layer, where the pressure sensitive adhesive layer includes a formulation of a pressure sensitive adhesive and a heat sensitive homeopathic formulation, where the pressure sensitive adhesive layer is processed at a temperature less than approximately 1000 F; and a releasable layer attached along the pressure sensitive adhesive layer. In some embodiments, the therapeutic patch detectably reduces nausea associated symptoms and menstrual cramping. In some embodiments, the pressure sensitive adhesive layer includes at least approximately 15% by weight of the heat sensitive homeopathic formulation. In some embodiments, the pressure sensitive adhesive layer includes at least approximately 5 to 20% by weight of the heat sensitive homeopathic formulation.

Therapeutic patches are presented including: a non-permeable sealing layer; a pressure sensitive adhesive layer bonded along the non-permeable sealing layer, where the pressure sensitive adhesive layer includes a formulation of a pressure sensitive adhesive and a heat sensitive homeopathic formulation, where the pressure sensitive adhesive layer is processed at a temperature less than approximately 1000 F; and a releasable layer attached along the pressure sensitive adhesive layer. In some embodiments, the therapeutic patch detectably reduces nausea associated symptoms and menstrual cramping. In some embodiments, the pressure sensitive adhesive layer includes at least approximately 15% by weight of the heat sensitive homeopathic formulation. In some embodiments, the pressure sensitive adhesive layer includes at least approximately 5 to 20% by weight of the heat sensitive homeopathic formulation.

Homeopathic water compositions are described, as well as beverage articles for making drinking water formulations with such compositions. One such beverage article includes a water bottle, and a dispensing cap adapted to be secured to the water bottle. The dispensing cap contains dried homeopathic composition-coated sucrose or sucrose/starch particles that are dispensable into water in the water bottle by user actuation of the dispensing cap, to constitute the homeopathic water formulation for consumption.